FDA Accepts LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s …

If approved, LEQEMBI IQLIK would be the first and only anti-amyloid treatment to offer at-home injection options for ...

2026 Retail Report: In-Store Experiences to Become More Fluid, Flexible and Feeling-Evoking, The Look Company Predicts

Retail Stores Are Phasing Out Digital Screens and Heavy Inventory to Make Space for Experiential Moments, Modular ...